Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Evaluation of Outcomes of Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).

Study Overview

• Status: Not yet recruiting
• Conditions: Hypoplastic Left Heart Syndrome
• Intervention / Treatment: Procedure: Fetal Aortic Valvuloplasty Procedure; Device: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter; Device: Trek RX and Mini Trek RX Coronary Dilatation Catheter

Detailed Description

The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic in Rochester

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria

• Pregnant women 18-45 years of age.
• Gestational age between 21 0/7 and 29 6/7 weeks of gestation
• The mother must be healthy enough to undergo surgery.
• The individual being enrolled must be able to provide informed consent.
• Dominant cardiac defect is valvar

• Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:

  • Retrograde flow in the transverse aortic arch
  • Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.

• Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:

  • Left ventricle long axis Z-score more than zero
  • Left ventricle short axis Z-score more than zero
  • Aortic annulus Z-score more than -3.5
  • Mitral valve annulus Z-score more than -2
  • Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).

Exclusion Criteria

• Patient is less than 18 years of age or more than 45 years of age.
• Contraindication to anesthesia or surgery
• Preterm labor or cervical length <20 mm at enrollement or uterine anomaly strongly predisposing to preterm delivery.
• Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
• Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.

• Cases with all the following criteria:

  • Left ventricle pressure ≤ 47 mmHg
  • MV dimension Z-score < 0.1
  • MV inflow time Z-score < -2

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group: Fetal Aortic Valvuloplasty; Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.	Procedure: Fetal Aortic Valvuloplasty Procedure; Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.; Device: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter; Balloon Catheter; Device: Trek RX and Mini Trek RX Coronary Dilatation Catheter; Coronary Dilation Catheter
No Intervention: Control Group: Expectant Management; Women diagnosed with HLHS will undergo expectant management with postnatal surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of cases in which the procedure was successful	Procedure success defined as the aortic valve was crossed and the balloon inflated with clear evidence of improvement of blood flow through the aortic valve and or new aortic valve regurgitation	Baseline
Number of cases in which a biventricular repair was achieved		Baseline
Number cases with pulmonary hypertension		Baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of cases delivered prematurely	Baseline
Number of cases with perinatal death	Baseline
Number of maternal complications	Baseline

Collaborators and Investigators

• Sponsor: Mauro H. Schenone
• Investigators: Principal Investigator: Mauro Schenone, MD, Mayo Clinic

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2024
• Primary Completion (Estimated): July 1, 2035
• Study Completion (Estimated): July 1, 2035

Study Registration Dates

• First Submitted: March 27, 2024
• First Submitted That Met QC Criteria: March 27, 2024
• First Posted (Actual): April 2, 2024

Study Record Updates

• Last Update Posted (Actual): April 10, 2024
• Last Update Submitted That Met QC Criteria: April 8, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Disease; Congenital Abnormalities; Heart Defects, Congenital; Cardiovascular Abnormalities; Syndrome; Hypoplastic Left Heart Syndrome
• Other Study ID Numbers: 22-012399

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes